en · de · es · fr · pt
aod-9604-notes.peptides5388.com › Guide › Identity And Molecular Context — Evidence Review

Identity And Molecular Context — Evidence Review

By Editorial Desk · published 2026-06-20 · last reviewed 2026-07-24 · Guide

mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Related pages on this site

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Supporting material

==== Cytochrome P450 modulation ==== It has been reported that bicalutamide may have the potential to inhibit the enzymes CYP3A4 and, to a lesser extent, CYP2C9, CYP2C19, and CYP2D6, based on in vitro research. However, no relevant inhibition of CYP3A4 has been observed in vivo with bicalutamide at a dose of 150 mg (using midazolam as a specific marker of CYP3A4 activity). In animals, bicalutamide has been found to be an inducer of certain cytochrome P450 enzymes. However, dosages of 150 mg/day or less have shown no evidence of this in humans. Bicalutamide has been identified as a strong CYP27A1 (cholesterol 27-hydroxylase) inhibitor in vitro. CYP27A1 converts cholesterol into 27-hydroxycholesterol, an oxysterol that has multiple biological functions including direct, tissue-specific activation of the ER (it has been characterized as a selective estrogen receptor modulator) and the liver X receptor. 27-Hydroxycholesterol has been found to increase ER-positive breast cancer cell growth via its estrogenic action, and hence, it has been proposed that bicalutamide and other CYP27A1 inhibitors may be effective as adjuvant therapies to aromatase inhibitors in the treatment of ER-positive breast cancer. In addition to CYP27A1, bicalutamide has been found to bind to and inhibit CYP46A1 (cholesterol 24-hydroxylase) in vitro, but this has yet to be assessed and confirmed in vivo.

== Morphology == This bacterium has a cell diameter is of 0.8–1.0 micrometers but does not have a definite length because of its multicellular filamentous structure. The bacterium is red to reddish-brown forms distinct red bacterial mats in the natural environment. R. castenholzii lacks internal vesicles, internal membranes, and complex structures. This species has gliding motility.

== Physiology == Proprioception is mediated by mechanically sensitive proprioceptor neurons distributed throughout an animal's body. Most vertebrates possess three basic types of proprioceptors: muscle spindles, which are embedded in skeletal muscles, Golgi tendon organs, which lie at the interface of muscles and tendons, and joint receptors, which are low-threshold mechanoreceptors embedded in joint capsules. Many invertebrates, such as insects, also possess three basic proprioceptor types with analogous functional properties: chordotonal neurons, campaniform sensilla, and hair plates. The initiation of proprioception is the activation of a proprioceptor in the periphery. The proprioceptive sense is believed to be composed of information from sensory neurons located in the inner ear (motion and orientation) and in the stretch receptors located in the muscles and the joint-supporting ligaments (stance). There are specific nerve receptors for this form of perception termed "proprioceptors", just as there are specific receptors for pressure, light, temperature, sound, and other sensory experiences. Members of the transient receptor potential family of ion channels have been found to be important for proprioception in fruit flies, nematode worms, African clawed frogs, and zebrafish. PIEZO2, a nonselective cation channel, has been shown to underlie the mechanosensitivity of proprioceptors in mice.

Sources: en.wikipedia.org

Supporting material

== Function == Like tendons, aponeuroses attached to pennate muscles can be stretched by the forces of muscular contraction, absorbing energy like a spring and returning it when they recoil to unloaded conditions. Also serving as an origin or insertion site for certain muscles e.g latissimus dorsi.

PMID 26494468.{{cite journal}}: CS1 maint: multiple names: authors list (link) Gitashri Naiya, Stephanie Kaypee, Tapas Kundu, Siddhartha Roy (March 2015). "A Constrained Helical Peptide Against S100A4 Inhibits Cell Motility in Tumor Cells". Chemical Biology & Drug Design. 86 (4): 945–950. doi:10.1111/cbdd.12553. PMID 25763457. S2CID 30631236.{{cite journal}}: CS1 maint: multiple names: authors list (link) Tanjore Balganesh, Tapas Kundu, Tushar Kanti Chakraborty, Siddhartha Roy (July 2014). "Drug Discovery Research in India: Current State and Future Prospects". ACS Medicinal Chemistry Letters. 5 (7): 724–6. doi:10.1021/ml500183c. PMC 4094254. PMID 25050153.{{cite journal}}: CS1 maint: multiple names: authors list (link) Siddhartha Roy, Tapas Kundu (February 2014). "Gene regulatory networks and epigenetic modifications in cell differentiation". IUBMB Life. 66 (2): 100–109. doi:10.1002/iub.1249. PMID 24574067. S2CID 205968012. Siddhartha Roy, Piya Ghosh, Neeladri Roy, Abhishek Mazumder, Koushik Roy, Asit Kumar Manna, Shampa Mallick, Israr Ahmed (May 2012). "Peptide based Molecules as Protein-Protein Interaction Inhibitors: Tools for Chemical Genetics and Therapy". Current Chemical Biology. 6 (2): 145–163. doi:10.2174/2212796811206020145.{{cite journal}}: CS1 maint: multiple names: authors list (link) DNA-Bound p53-DNA-Binding Domain Interconverts between Multiple Conformations: Implications for Partner Protein Recognition.

== Additional functions == The ILEA had its own schools broadcasting service, the Educational Television Service, based in the former Tennyson Secondary School, Thackeray Road, SW8. The television centre had two functional television studios, a training studio, a master control and sound and vision mixing suites. At one stage this was believed to be the largest closed-circuit television system in the world. The first transmission took place on 16 September 1969 and the Television Service ran until 1977. When the Post Office, whose cabling was used for the distribution, wanted to withdraw from its contract in the late 1970s, the programming was transferred to VHS tapes and the CCTV network closed down. The Cockpit Theatre, Marylebone (also known at the Cockpit Youth and Arts Centre), in Gateforth Street, London, NW8, was built for the ILEA on the edge of the Lisson Green estate in 1969–70. It was designed as a Theatre in the round by Edward Mendelsohn. The ILEA created the first Theatre in Education company to be entirely housed within a local education authority. It employed seven actor-teachers and a stage manager and focused its work on secondary schools and Further Education. As well as traditional T.I.E. the Cockpit team used the approach to develop shows analysing set texts. When ILEA was abolished in 1990, ownership of the theatre transferred to the London Borough of Westminster. The ILEA had a planetarium, based at Wandsworth School. It was opened by the Astronomer Royal Sir Richard Woolley on 19 May 1966.

== Toponymy == The origin of the name Billericay is unclear. It was first recorded as Byllyrica in 1291. The urban settlement, which was within the manor and parish of Great Burstead, was one of many founded in the late 13th century in an already densely populated rural landscape. Several suggestions for the origin of the place name include:

Sources: en.wikipedia.org

Notes from published material

=== Immunodeficiency === In individuals lacking functional HLA-DM molecules, improper antigen presentation occurs, resulting in unwanted immune responses or lack of a response when danger is present. This has been shown experimentally through mouse knockout models. There will be an increase of CLIP, instead of peptide, presentation on APC surfaces. This can result in autoimmunity, if a T cell receptors recognize CLIP as a harmful antigen. There could also be no protein presentation at all, resulting in a lack of immune response.

Portugal's territory comprises mainland Portugal and the Azores and Madeira archipelagos. The mainland, commonly referred to as Continental Portugal, is located in the southwest of the Iberian Peninsula in Southwestern Europe, while Madeira and the Azores lie in the Atlantic Ocean. Portugal's land area is 92,225 km2 (35,608 sq mi), although Portuguese law defines the country's size as 156,597 km2 (60,462 sq mi) which includes about 64,000 km2 (24,711 sq mi) of ocean waters. Portugal's exclusive economic zone extends 1,727,408 km2 (666,956 mi2), making it one of the largest in the European Union. The country is over two-thirds wilderness, almost one-fourth agricultural, and the remainder human settlements. Portugal's highest point is the summit of Mount Pico, located on Pico Island in the Azores, which rises to an elevation of 2,351 m (7,713 ft) above sea level. Portugal can be divided into four morphostructural units: the Hesperian Massif, which occupies most of mainland Portugal; the sedimentary borderlands of the massif, forming the Lusitanian and Algarve basins; the Lower Tagus and Alvalade sedimentary basins; and the volcanic submarine ranges that form the Azores and Madeira. Its geological and geomorphological features are largely the product of the Variscan, responsible for the formation of the Hesperian Massif, and later the Tethys–Atlantic cycle, responsible for the remaining units.

As indicated by the National Academy of Sciences report Strengthening Forensic Sciences in the United States, part of the problem is that many traditional forensic sciences have never been empirically validated; and part of the problem is that all examiners are subject to forensic confirmation biases and should be shielded from contextual information not relevant to the judgment they make. Studies of rape-related injury prevalence and frequency across race have reported racial differences when studying adult rape victims, with higher percentage of white victims sustaining injuries and/or white victims sustaining a higher number of injuries than Black victims. However, current forensic examination techniques may not be sensitive to all injuries across a range of skin colors. One study found that it was dark skin color, not race, that strongly correlated with decreased injury prevalence, concluding therefore, that sexual assault forensic examiners "may not be able to detect injury in women with dark skin as readily as women with light skin, leading to health disparities for women with dark skin" (Sommers et al., 2009). In clinical practice, for patients with darker skin, one study recommends that attention must be paid to the thighs, labia majora, posterior fourchette and fossa navicularis, so that no rape-related injuries are missed upon close examination.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network